Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | FLT1 | P17948 | 3/20 | 0.36 |
| ▸ | FLT4 | P35916 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27739070 | 1.00 | CA12 (0.44) | CA12CA9NPC1SMN1; SMN2HPGD | |
| SCHEMBL4620075 | 0.88 | FLT1 (0.43) | NPC1SMN1; SMN2HPGDRAB9AFLT1 | |
| SCHEMBL27717788 | 0.86 | ALDH1A1 (0.36) | NPC1SMN1; SMN2HPGDRAB9AFLT1 | |
| SCHEMBL5419492 | 0.86 | ALDH1A1 (0.36) | NPC1SMN1; SMN2HPGDRAB9AFLT1 | |
| SCHEMBL5411577 | 0.85 | CYP1A1 (0.41) | CA12CA9NPC1SMN1; SMN2RAB9A | |
| SCHEMBL27717766 | 0.85 | CYP1A1 (0.41) | CA12CA9NPC1SMN1; SMN2RAB9A | |
| SCHEMBL27717778 | 0.81 | CA12 (0.48) | CA12CA9RAB9AFLT1FLT4 | |
| SCHEMBL4619057 | 0.81 | CA12 (0.48) | CA12CA9RAB9AFLT1FLT4 | |
| SCHEMBL4619090 | 0.81 | FLT1 (0.48) | NPC1SMN1; SMN2HPGDRAB9AFLT1 | |
| SCHEMBL4619085 | 0.81 | FLT1 (0.48) | NPC1SMN1; SMN2HPGDRAB9AFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | claimed |
| EP-1888519-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2007054139-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | CA12 1869/4885CA9 771/4885NPC1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.